Navigation Links
Heart Center at Sinai Conducts Landmark Study on Aspirin Resistance

With coronary artery disease the single leading cause of death in the western world, aspirin is used by millions of patients as a prevention and treatment regiment for this deadly disease.// In the largest study to date on the effectiveness of aspirin, researchers at Sinai Hospital of Baltimore recently demonstrated that aspirin resistance is rare, less than 5 percent, at all doses (81 mg, 162 mg and 325 mg) in patients with heart disease.

Most coronary artery disease deaths are caused by platelets sticking together and forming blood clots (thrombosis) that block blood flow within arteries, resulting in a heart attack. By inhibiting clotting, aspirin keeps platelets from sticking together by specifically blocking an important enzyme, COX-1.

“The occurrence of clotting in patients taking aspirin therapy has been attributed to the failure of aspirin blocking its target and is a hot topic in cardiovascular disease today,” said Paul Gurbel, MD, lead investigator for the study and the Helen Dalsheimer director of the Division of Cardiology and director of the Center for Thrombosis Research at Sinai Hospital of Baltimore. “However, our data suggest that aspirin blocks COX-1 with high efficiency.”

The team at the Center for Thrombosis Research at Sinai Hospital studied 120 patients with a history of coronary artery disease treated with aspirin. All patients were randomly placed on 81 mg, 162 mg and 325 mg of aspirin daily for four weeks each for a total of 12 weeks. Then the response to aspirin was tested by multitude methods. When measuring the ability of aspirin to block its target, COX-1, it was found highly effective at all dose levels.

“The research also shows that aspirin may be effective at blocking other pathways that promote platelet activation, independent of COX-1. Further research is now under way to better understand these additional pathways that may cause clotting in patients in an effort to continue to improve patient outcomes,” said Gurbel.



Source-EurekalertSRM
'"/>




Related medicine news :

1. One in Three Heart Attack Patients Have No Chest Pains
2. Epileptic Seizures Can Be Due to Heart Problem
3. Bypass Heart Surgery Performed Without General Anesthesia
4. New CPR Guidelines issued by Heart Association
5. White Cells Count Can Predict Heart Attack Death Risk
6. Vitamins-The answer to Heart Disease?
7. Fight Heart disease and Pain with Meditation
8. Heart disease in the newborn is related to maternal malnutrition
9. New drug to treat Heart Attack and damaged tissue
10. Heart disease threat starts early in life for Diabetics
11. Mechanical Heart
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/28/2017)... Manhattan New york (PRWEB) , ... April 28, ... ... is pleased to announce that Aditya Patel M.D. has joined the revolutionary endoscopic ... fellowship training and board certification in Interventional Pain Medicine. The patented, revolutionary eDiscSculpt ...
(Date:4/28/2017)... ... April 28, 2017 , ... People are starting to ... “Wearing a hearing aid doesn’t have the stigma it had when great-grandpa wore his ... of Greater Boston, in a NALA North American Speaker Series (NASS) segment. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... their work assisting the Brooke Grove Foundation implement a Microsoft Dynamics GP solution ... Solutions, a leading ERP expert that specializes in long-term care, Brooke Grove now ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
(Date:4/27/2017)... Minnesota (PRWEB) , ... April 27, 2017 , ... ... and her husband Dan Gasby the 2017 Public Leadership in Neurology Award (PLINA). ... Woodruff, retired professional athlete Tedy Bruschi, Vice President Walter Mondale, actor Michael J. ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology: